Calcium carbonate/esomperazole - Addpharma
Alternative Names: AD-206Latest Information Update: 24 Jan 2023
At a glance
- Originator Addpharma
- Class Antiulcers
- Mechanism of Action Antacids; Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Reflux oesophagitis
Most Recent Events
- 24 Jan 2023 AD 206 is still in preregistration stage for Reflux oesophagitis in South Korea (Addpharma pipeline, January 2023)
- 17 Dec 2020 AD 206 is available for licensing as of 17 Dec 2020. http://www.addpharma.co.kr/
- 01 Sep 2020 Preregistration for Reflux oesophagitis in South Korea (PO) (Addpharma pipeline, December 2020)